Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06066177
Collaborator
(none)
100
57

Study Details

Study Description

Brief Summary

This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of cardiovascular outcomes in Patients Presented with myocardial infarction with nonobstructive coronary arteries.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Triglyceride glucose index TyG

Detailed Description

Acute myocardial infarction (AMI) remains the leading causes of high morbidity and mortality worldwide . Recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized because of the widespread use of coronary angiography. MINOCA occurs in 5%-10% of all AMI and they are younger and more often women compared to patients with AMI and obstructive coronary artery disease (CAD). The underlying causes of MINOCA are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA . Of note, several studies have found that the prognosis of MINOCA is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (CV) events despite the optimal secondary prevention treatments . Thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in MINOCA population.

Insulin resistance (IR), a critical mechanism of the pathogenesis of diabetes, not only contributes to the development of cardiovascular diseases (CVD), but also significantly correlates with adverse CV outcomes. Additionally, IR often coexists with obesity, hypertension, and dyslipidemia , and all of these are well-known risk factors of CVD. Recently, the triglyceride-glucose (TyG) index derived from fasting triglyceride (TG) and fasting blood glucose (FBG) levels has been proposed as a new and valid surrogate indicator of IR . Till now, many studies have found that the TyG index is positively correlated with metabolic disorders, arterial stiffness , carotid atherogenesis , coronary artery calcification , and subclinical or symptomatic CAD. Moreover, growing evidence has showed that the TyG index is an independent predictor of poor CV outcomes in general population and in different cohorts with CAD, including patients with AMI or acute coronary syndrome (ACS) with or without diabetes

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With Myocardial Infarction With Nonobstructive Coronary Arteries
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Aug 1, 2028
Anticipated Study Completion Date :
Oct 1, 2028

Outcome Measures

Primary Outcome Measures

  1. Incidence of major adverse cardiovascular events (MACE) [along one year follow up .]

    including all-cause death, reinfarction, stroke, re-intervention hospitalization for unstable angina or heart failure)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • All patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA)

  • clinical symptoms

  • ECG : ischemic changes with or without ST segment elevation

  • Echocardiograpy : segmental wall motion abnormalities (SWMA)

  • positive cardiac enzymes

  • Coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%)

Exclusion Criteria:
  • All non confirmed diagnosis of MINOCA

  • cardiac

  • non-ischemic cardiomyopathies

  • non-cardiac

  • pulmonary embolism

  • stroke

  • sepsis

  • ARDS

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Principal Investigator: Ayman khairy Mohamed Hassan, Cardiology department
  • Principal Investigator: Khaled Mohamed Abdullah Mohamed, Cardiology department

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ahmed Gamal Thabit Mohamed, Resident , department of Cardiology،Principal Investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT06066177
Other Study ID Numbers:
  • TyG index and MINOCA
First Posted:
Oct 4, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ahmed Gamal Thabit Mohamed, Resident , department of Cardiology،Principal Investigator, Assiut University

Study Results

No Results Posted as of Oct 10, 2023